Introduction
Thymocytes pass through a series of developmental progressions which ensure the production of a large and genetically diverse population of immunologically competent T cells. The expansion, genetic diversification and immunological selection of thymocytes has to be rigorously regulated to prevent the emergence of either self-reactive or malignant clones. At the b selection checkpoint, double negative (DN, CD4 À CD8 À ) thymocytes are challenged for T-cell receptor (TCR)b functionality. If TCRb is productively rearranged, it assembles with CD3 and pTa to form a constitutively signaling pre-TCR which confers cell division, apoptosis suppression and differentiation into the intermediate single positive (ISP, CD4 þ or CD8 þ ) and then double positive (DP, CD4 þ CD8 þ ) stages of thymocyte development (Kruisbeek et al., 2000; Michie and ZunigaPflucker, 2002) . Subsequent rearangement and surface expression of TCRa generates a diversity of TCRs. DP thymocytes bearing self-reactive TCRs are eliminated by negative selection, while those with TCRs capable of interacting with MHC in the absence of antigen undergo positive selection, resulting in survival, limited proliferation and maturation into single positive (SP, CD4 þ or CD8 þ ) thymocytes (Sebzda et al., 1999; Hogquist, 2001) .
RasGRP1 is a Ras GTPase-specific guanine nucleotide exchange factor which is positively regulated by TCR at both the transcriptional and biochemical levels. Pre-TCR ligation or TCR-MHC interactions result in transcriptional induction of the RasGRP1 gene (Norment et al., 2003; Tiong Ong et al., 2003) , and biochemical activation of RasGRP1 is dependent on signal transduction from TCR via phospholipase Cg1 Bivona et al., 2003) . Although RasGRP1 is not required for pre-TCR-directed b selection in normal mice (Dower et al., 2000) , constitutive transcription of RasGRP1 from a transgene confers partial developmental progression up to the DP stage in the absence of pre-TCR (Norment et al., 2003) . The efficiency of TCR-directed positive selection of DP thymocytes is severely compromised in RasGRP1-deficient mice (Dower et al., 2000; Priatel et al., 2002; Layer et al., 2003) . Conversely, RasGRP1 transgenic mice have increased numbers of CD8 SP thymocytes that have enhanced proliferative and survival responses to TCR ligation (Norment et al., 2003) . Thus, RasGRP1 serves to transduce signals from pre-TCR and TCR which allow thymocytes to pass through the two critical checkpoints during T-cell development, b selection and positive selection.
Activating point mutations in N-Ras occur in about 10% of human T lymphocytic leukemias (Ahuja et al., 1990; Yokota et al., 1998; Kawamura et al., 1999) , and transgenic mice expressing mutationally activated NRas or H-Ras have high incidences of thymic lymphomas (Dunbar et al., 1991; Hawley et al., 1995; Swat et al., 1996; Curtis et al., 1997; Adams et al., 1999) . RasGRP1 is one of many Ras-regulating proteins (Quilliam et al., 2002) whose structural mutation or aberrant expression could potentially mimic the oncogenicity of Ras mutations. RasGRP1 is highly expressed in most cases of human acute T lymphocytic leukemias (Yeoh et al., 2002) , which originate predominantly from transformed thymocytes (Asnafi et al., 2002) . More direct evidence indicating that RasGRP1 has the potential to act as a dominant oncogene in T cells has been obtained from analyses of murine lymphomas which arose as a consequence of retroviral insertional mutagenesis (Li et al., 1999; Kim et al., 2003) . Of 48 T-cell lymphomas occurring after infection of neonatal mice with the SL3 retrovirus, five had proviral insertions near the RasGRP1 gene (Kim et al., 2003) . Although these lymphomas have not been characterized in terms of cell phenotypes or RasGRP1 expression, it is expected that they arose due to the imposition of the proviral pattern of expression on the adjacent RasGRP1 gene.
In this paper, we demonstrate that deregulated expression of RasGRP1 via a transgene initiates the development of thymic lymphomas and T-cell leukemias. By crossing the RasGRP1 transgene onto genetic backgrounds providing expression or absence of positively selectable TCRs, we found that lymphomagenesis via RasGRP1 was not dependent on positive selection, appeared to originate in immature DN or ISP thymocytes, and occurred independently of either TCR or pre-TCR. These results indicate that the oncogenic potential of RasGRP1 during thymocyte development reflects its ability to confer survival and proliferation on immature thymocytes, rather than its enhancement of TCRdirected positive selection of DP and SP thymocytes.
Results

RasGRP1 transgenic mice develop thymic lymphomas
Three different RasGRP1 transgenic mouse lines, AM1268, 13H and 293H, were analysed for the development of T-cell malignancies. There was an elevated death rate in all three lines, most notably in the 13H line where 50% of the mice died within 130 days of birth (Figure 1 ). Death was typically preceded by a period of 1-2 days during which the mouse would be generally healthy but would show signs of labored breathing. Mice with these symptoms were killed and analysed. In all three lines, the afflicted mice invariably had thymic lymphomas, with elevated numbers of thymocytes ranging from two-to 10-fold above those in nontransgenic littermates. The phenotypes of a representative set of six thymic lymphomas from the 13H line are shown in Figure 2a , along with a nontransgenic thymus and a thymus from a healthy 13H transgenic mouse. The lymphomas had variable phenotypes, with expansion occurring in combinations of DN, DP and/or SP thymocytes. The lymphomas contained a high proportion of proliferative cells, while normal (nonlymphomic) transgenic thymocytes were (Michie and Zuniga-Pflucker, 2002) . However, there was high CD25 expression on DP thymocytes in seven out of nine 13H lymphomas (example in Figure 2d ). Induction of CD25 expression accompanies T-cell activation via TCR. However, another marker of T-cell activation, loss of CD62L expression (Dailey, 1998) , did not accompany thymocyte transformation in RasGRP1 transgenic thymocytes ( Figure 2d ). Activation of DP thymocytes via positively selecting TCR triggers increased expression of CD69 and CD5 (Azzam et al., 1998; Anderson et al., 1999) , but both of these markers were low in transformed DP thymocytes ( Figure 2d ). Therefore, while the transformed DP thymocytes are activated in terms of being proliferative and enlarged, they do not express a full set of markers associated with TCR-dependent activation.
In some mice with large thymic lymphomas, the spleen, lymph nodes and/or bone marrow were infiltrated with enlarged lymphocytes resembling the transformed cells in the thymic lymphoma ( Figure 2e , and data not shown). Cells from thymic lymphomas or infilitrated lymph nodes survived and proliferated in culture medium, resulting in the establishment after 2-3 weeks of rapidly dividing, clonable cell lines with CD4 and CD8 expression patterns resembling those of the transformed cells which initiated the cultures (data not shown). Therefore, the hallmarks of transformation of the thymic lymphoma cells included loss or distortion of normal differentiation, deregulated proliferation, dissemination as peripheral leukemias, and ability to survive and proliferate indefinitely in culture in the absence of supportive cytokines or stromal cells.
We used flow cytometric analysis of TCR Vb usage (Cleverley et al., 2000) to determine the clonality of lymphomas arising in RasGRP1 transgenic mice. Normally, about 15% of SP thymocytes in C57BL/6 mice have the Vb8 rearrangement of the TCRb gene. If a population of cells is clonally derived from a single thymocyte which had undergone TCRb rearrangement and allelic exclusion to fix its Vb usage, the population will exhibit loss of heterogeneity of Vb expression. In about 85% of cases, this will result in the absence of Vb8 expression in the clonal population, and in about 15% of cases all of the SP cells will express Vb8. Four lymphomas from 13H transgenic mice contained transformed SP thymocytes with moderate to high TCRb expression and therefore could be assessed for clonality. In all four cases, the CD8 SP thymocytes of the lymphomas had ratios of TCR-Vb8 to total TCRb that were 10-50-fold lower than the ratio of 0.15 observed for normal CD8 SP thymocytes (Table 1 ). The lack of representation of Vb8 indicates that the lymphomas originated from one or a few thymocytes which had undergone TCRb rearrangement and had subsequently undergone clonal expansion.
High transgenic RasGRP1 expression correlates with the initiation of lymphomagenesis
The transgene-encoded RasGRP1 protein is expressed at moderate to low levels in all thymocyte subsets of normal (lymphoma-free) mice of the AM1268 line (Figure 3 ), resulting in a net doubling of RasGRP1 protein levels relative to nontransgenic thymocytes (Norment et al., 2003) . Transgenic RasGRP1 expression was similar in the 293H line except for minimal expression in DP thymocytes (Figure 3 , mouse S), whereas in the 13H line expression of transgenic RasGRP1 protein was detected only in a minor portion In contrast, transgenic RasGRP1 expression was high in all transformed thymocytes within lymphomas arising in RasGRP1 transgenic mice (e.g. Figure 3 , mice E and T). Therefore, lymphomagenesis is accompanied by a transition from low or moderate to high levels of expression of the RasGRP1 transgene. The variable incidences of lymphomas in the three different transgenic lines may reflect an integration site-dependent variation in the probability of the transgene undergoing a random transition to high expression.
To determine if acquisition of high RasGRP1 expression was an initial or late event during lymphoma development, we examined transgenic RasGRP1 expression in transformed versus nontransformed thymocytes in mice with very early stage lymphomas. An example is mouse H of the 13H line, which had a normal complement of DN and CD4 SP thymocytes but had a small increase in DP thymocytes and an atypical population of CD8 þ CD4 À thymocytes (Figure 3) . Most of the CD8 þ CD4 À thymocytes and a minority of the DP thymocytes in mouse H had high forward light scatter, indicating transformation. In this mouse, all DN and CD4 SP thymocytes had undetectable transgenic RasGRP1 expression, while the atypical CD8 þ CD4 À thymocytes and a discrete minority of DP thymocytes had high expression (Figure 3) . The DP thymocytes with no detectable expression of transgenic RasGRP1 had the low light scatter which characterizes quiescent DP thymocytes ( Figure 3 , bottom histogram). In contrast, the DP thymocytes with high transgenic RasGRP1 expression had high light scatter, indicating transformation. This analysis indicates that the thymus of mouse H contained transformed DP and CD8 þ CD4 À thymocytes with high transgene expression, coexisting with a larger number of normal DN, DP and CD4 SP thymocytes which retained low or nil transgene expression. The precise correlation between high RasGRP1 expression and thymocyte transformation observed in this and all other analysed mice, including other early stage lymphomas, demonstrates that high RasGRP1 expression is an early and thus potentially causative event in lymphomagenesis.
Testing the role of TCR-mediated positive selection in lymphomagenesis via RasGRP1
RasGRP1 is activated in response to TCR ligation Bivona et al., 2003) , and transduces signals that enable TCR-mediated positive selection at the DP stage (Dower et al., 2000; Priatel et al., 2002; Layer et al., 2003) as well as enhanced survival and TCR-induced proliferation at the SP stage (Norment et al., 2003) . This raised the question of whether the lymphomas in RasGRP1 transgenic mice were caused by amplified signaling downstream of TCR, leading to an exaggeration of the survival and proliferative responses which confer positive selection. If enhancement of positive selection by RasGRP1 plays an initiating role in lymphoma development, then increasing the proportion of thymocytes undergoing positive selection in RasGRP1 transgenic mice should increase the incidence of lymphomas. In female mice transgenic for the MHC class I-specific H-Y TCR, a high proportion of DP thymocytes are positively selected on H-2D b and differentiate into mature CD8 SP thymocytes (Kisielow et al., 1988) . The efficiency of positive selection of DP thymocytes expressing the H-Y TCR on H-2D b is attenuated in RasGRP1-deficient mice (Priatel et al., 2002) and is enhanced in AM1268 RasGRP1 transgenic mice (data not shown). Expression of the H-Y TCR markedly increased and accelerated the incidence of thymic lymphomas in female mice of the AM1268 RasGRP1 transgenic line (Figure 4 , in comparison to Figure 1 ). The phenotype of one RasGRP1 Tg þ /H-Y TCR þ female with a large thymic lymphoma is shown in Figure 5 . The lymphoma cells are a combination of DP and CD8 SP, as might be expected if they arose from exaggerated positive selection of the H-Y TCR which directs survival of DP thymocytes and their differentiation into the CD8 lineage. However, none of the CD8 SP cells of this mouse expressed CD69, which is induced in response to RasGRP1-dependent positive selection of the H-Y TCR (Priatel et al., 2002) . The lymphoma CD8 SP cells also differed from the positively selected CD8 SP thymocytes of H-Y TCR transgenic mice by being predominantly TCR low and CD24 high . TCR expression is high and CD24 expression is low on mature CD8 SP thymocytes which have been positively selected via H-Y TCR (Priatel et al., 2002) , but this pattern is reversed on ISP thymocytes which are undergoing progression from the DN to DP stages (Egerton et al., 1990) . Lack of CD69 expression, low TCR expression and high CD24 expression indicate that the CD8 þ CD4 À thymocytes of the lymphoma were not generated through the process of TCR-mediated Since the H-Y TCR recognizes a male-specific antigen, in male H-Y TCR þ mice thymocytes are deleted by negative selection as soon as they reach the DP stage (Kisielow et al., 1988) . As a consequence, there are very few DP thymocytes and no positive selection can occur. If lymphomagenesis is driven by the enhancement of positive selection by RasGRP1, male RasGRP1 Tg þ /H-Y TCR þ mice would not be expected to get thymic lymphomas. However, the death rate was very high in RasGRP1 Tg þ /H-Y TCR þ male mice (Figure 4) . Three asymptomatic male RasGRP1 Tg þ /H-Y TCR þ mice were analysed. Of these, two had very small thymuses, very few DP thymocytes and no mature SP thymocytes (Figure 6a , top right and bottom left panels), typical of male H-Y TCR þ mice undergoing 
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À thymocytes with high light scatter and retention of H-Y TCR expression, while its spleen and lymph nodes were massively infiltrated with cells phenotypically identical to the transformed cells in the thymus (Figure 6b , and data not shown). In this mouse, negative selection apparently constrained the proliferation of transformed cells within the thymus, while escape of transformed cells from the thymus resulted in an aggressive T-cell malignancy due to lack of negative selection in peripheral lymphoid organs.
In combination, the phenotypes of normal and transformed thymocytes in H-Y TCR þ female and male mice indicate that RasGRP1-mediated lymphomagenesis can originate in thymocytes which are not undergoing positive selection.
TCR or pre-TCR are not required for lymphomagenesis in RasGRP1 transgenic mice
The experiments with H-Y TCR transgenic mice indicated that RasGRP1 can drive lymphomagenesis independently of its ability to enhance TCR-dependent positive selection, but also demonstrated that the H-Y TCR transgene accelerated RasGRP1-mediated lymphomagenesis. This transgenic TCR is ectopically expressed in DN and ISP thymocytes, and provides survival and proliferative signals that mimic pre-TCR (Von Boehmer et al., 2003) . This raised the possibility that endogenous TCR or pre-TCR might also collaborate with RasGRP1 in promoting lymphomagenesis, potentially by triggering RasGRP1 activation via PLCg1 Bivona et al., 2003) .
To directly test the requirement for either pre-TCR or TCR in RasGRP1-mediated lymphomagenesis, we crossed the RasGRP1 transgene onto a Rag2 À/À background, which prevents TCR gene rearrangements. In normal Rag2
À/À mice, thymocyte development is arrested at the DN stage (Figure 7a, left panel) . In RasGRP1 Tg þ /Rag2 À/À mice, the developmental block due to pre-TCR deficiency was over-ridden, resulting in a 10-fold expansion of the DN population and the generation of ISP and DP thymocytes (Figure 7a , middle panel). This reflects the ability of RasGRP1 to provide proliferative and developmental progression signals which partially compensate for pre-TCR deficiency (Norment et al., 2003) . The RasGRP1 Tg þ / Rag2 À/À mice had a high death rate (Figure 7b ) due to thymic lymphomas comprised of transformed DN, ISP and DP thymocytes (example shown in Figure 7a , right panel). This demonstrates that the RasGRP1 transgene can cause lymphomagenesis in the absence of abTCR, gdTCR or pre-TCR. The large numbers of DN, ISP and DP thymocytes in the RasGRP1 Tg þ /Rag2 À/À mice prior to the onset of overt lymphomagenesis suggests that one mechanism by which deregulated RasGRP1 expression can initiate lymphomagenesis is by expanding the pool of proliferating immature thymocytes.
Discussion
High RasGRP1 expression in most T acute lymphocytic leukemias and the presence of proviral insertions at the RasGRP1 locus in retrovirally induced murine thymic lymphomas suggested that deregulated and high RasGRP1 expression could contribute to the initiation or progression of T-cell malignancies. The occurence of thymic lymphomas in three independent transgenic mouse lines directly demonstrates the causative role of RasGRP1 in the development of thymic lymphomas and derivative peripheral T-cell leukemias. The correlation between high transgene expression and thymocyte transformation, and our ability to measure both at the single cell level, allowed us to address the question of whether high RasGRP1 expression contributed to the initiation versus progression of thymic lymphomas. We found that transformed thymocytes in very early stage lymphomas had high expression of transgenic RasGRP1, indicating that RasGRP1 contributes to the initiation of lymphomagenesis. This presumably reflects the ability of RasGRP1 to stimulate signaling through Ras GTPases, as thymic lymphomas are also induced by expression of constitutively activated mutants of N-or H-Ras (Hawley et al., 1995; Swat et al., 1996; Curtis et al., 1997) , and by deregulated mutants of the Raf-1 and MEK1 kinases (Iritani et al., 1997 (Iritani et al., , 1999 , which are activated downstream of Ras GTPases. However, overexpression of RasGRP1 is unlikely to be sufficient to initiate lymphomagenesis. Cooperating mutations in other genes may have to occur prior to or after the transition to high RasGRP1 expression in order for overt transformation of thymocytes to occur. Thymocytes that acquired high RasGRP1 expression but lacked essential cooperating mutations might not be selectively expanded and therefore their high expression of RasGRP1 would go unnoticed. In retrovirally induced T-cell lymphomas, proviral insertion at the RasGRP1 locus can be accompanied by proviral insertions at known oncogenes, that is, Runx3, Fos, Pim1 (Kim et al., 2003) . In these cases, it is very likely that the other provirally marked oncogenes are cooperating with RasGRP1 in causing the initiation or progression of lymphomagenesis. RasGRP1 overexpression may contribute to the survival and proliferation of the transformed thymocytes, while additional oncogenic mutations could be required to suppress differentiation, which normally accompanies and limits RasGRP1-mediated expansion and positive selection of thymocytes at the DN, DP or SP stages (Norment et al., 2003) .
In T-cell lines, RasGRP1 activation is dependent on signaling via ligated TCR Bivona et al., 2003) . RasGRP1 is required both for positive selection through most TCRs and for proliferative responses to TCR ligation (Dower et al., 2000; Priatel et al., 2002; Layer et al., 2003) . RasGRP1 transgenic mice accumulate CD8 SP thymocytes with TCR levels which would normally be too low to confer positive selection, but nonetheless have a hyperactive proliferative response to TCR ligation in vitro (Norment et al., 2003) . In combination, these observations suggested that lymphomagenesis could be caused by an exaggerated form of RasGRP1-mediated, TCR-dependent positive selection at the DP stage, potentially combined with proliferative responses extending into the SP stage. We found that RasGRP1 cooperated with the positively selected H-Y TCR in inducing lymphomas in female mice. However, the majority of CD8 , indicating that they had not been positively selected and were probably derived from ISP thymocytes which would not be developmentally mature enough to undergo positive selection. Furthermore, the RasGRP1 transgene and the H-Y TCR were also cooperative in promoting lymphomagenesis in negatively selecting male mice, in which positive selection was precluded and DP thymocytes were severely depleted. Rather than implicating positive selection, these results indicated that RasGRP1-induced lymphomas originate from DN or ISP thymocytes, prior to the expression of ab TCR and the acquisition of susceptibility to positive selection.
To determine if either TCR or pre-TCR were required for RasGRP1-induced lymphomagenesis, we crossed the RasGRP1 transgene onto a Rag2 À/À background to preclude rearrangement of TCR genes. The RasGRP1 transgenic/Rag2 À/À mice did get thymic lymphomas, at a rate that was markedly accelerated relative to RasGRP1 transgenic/Rag2 þ mice of the same line. In contrast to Rag2 À/À mice in which thymocyte development is arrested at the DN stage due to pre-TCR deficiency, the RasGRP1 transgenic/Rag2 À/À mice had large numbers of DN, ISP and DP thymocytes, even prior to the onset of lymphomagenesis. This suggests that deregulated expression of RasGRP1 contributes to the initiation of lymphomas by triggering proliferation of DN and ISP thymocytes, thus expanding the pool of immature thymocytes that are susceptible to transformation. This mechanism also explains the ability of the H-Y transgenic TCR to cooperate with RasGRP1 in causing lymphomas. Abnormally early expression of the transgenic H-Y TCR results in excessive accumulation of DN thymocytes (Von Boehmer et al., 2003) , apparently due to perturbed gd versus ab lineage commitment (Bruno et al., 1996; Terrence et al., 2000; Erman et al., 2002) . When combined with the ability of deregulated expression of RasGRP1 to stimulate DN and ISP proliferation, this effect of the H-Y TCR would be expected to increase the probability of lymphoma initiation.
Materials and methods
Generation and breeding of RasGRP1 transgenic mice
The transgenic expression vector p1017C was derived from p1017D (Norment et al., 2003) by inserting the XbaI fragment of the IgH enhancer upstream of the lck promoter, exactly as described (Iritani et al., 1997) . The N-terminally HA-tagged RasGRP1 cDNA was inserted into p1017C at the MluI and SalI sites between the b-globin intron and the polyadenylation signal of the human growth hormone gene. The 13H and 293H founder mice were obtained by microinjecting the NotI fragment from p1017C/HA-RasGRP1 into (C57BL/ 6 Â DBA) Â C57BL/6 F 1 embryos, and the transgenic lines were established by breeding to C57BL/6. The generation of AM1268 transgenic mice was described previously (Norment et al., 2003) .
RasGRP1 transgenic mice were bred with Rag2 À/À C57BL/6 mice (Shinkai et al., 1992 . All H-Y TCR mice were on a H-2D b background. Rag2 À/À and Rag2 À/À H-Y-TCR C57BL/6 mice were purchased from Taconic Farms (Germantown, NY, USA). Mice were housed under pathogen-free conditions.
Flow cytometry analysis
The following antibody conjugates were from BD Pharmingen (San Diego, CA, USA): anti-CD4-CyChrome, anti-CD4-APC, anti-CD8a-APC, anti-CD8a-PE, anti-TCRb-FITC, anti-TCRVb8-FITC, anti-CD24-FITC, anti-CD69-FITC, anti-CD25-FITC, anti-CD5-FITC, anti-CD62L-FITC. H-Y TCR expression was detected with FITC-T3.70 (eBioscience, San Diego, CA, USA). After staining with antibodies and propidium iodide, cells were analysed using a FACScalibur flow cytometer and CellQuest software (Becton Dickinson, San Jose, CA, USA). In the displayed analyses, nonviable cells which were propidium iodide positive or had very low forward light scatter were gated out.
Intracellular staining/flow cytometry detection of RasGRP1 transgenic protein
Thymocytes were isolated, rinsed once with HBSS/2% FBS and incubated with anti-CD4-APC and anti-CD8-PE for 30 min. Thymocytes were then rinsed twice with HBSS/2% FBS and fixed with cytofix/cytoperm solution (BD Pharmingen) for 20 min. Fixed thymocytes were rinsed twice with 1 Â cytoperm/wash solution and incubated with FITC-conjugated anti-HA antibody (Covance Research Products, Berkeley, CA, USA) for 30 min. Stained thymocytes were rinsed twice with 1 Â cytoperm/wash and suspended in HBSS/2% FBS and analysed by flow cytometry.
Analysis of TCR-Vb8 to total TCRb ratios
Thymocytes were stained with anti-CD4-CyChrome and antiCD8a-APC, in conjunction with either anti-TCRb-FITC or anti-TCR-Vb8-FITC. Transformed thymocyte populations were gated by CD4, CD8 and/or by high light scatter as needed to segregate them from nontransformed thymocytes. The proportion of gated cells expressing TCR-Vb8 or TCRb were quantified by histogram analysis.
Cell cycle analysis
Thymocytes were isolated, rinsed in HBSS/2% FBS and fixed with ice-cold 70% ethanol and left at 41C overnight. Fixed thymocytes were rinsed twice with HBSS and incubated with propidium iodide (5 mg/ml) and RNase A (200 mg/ml) at 41 for at least 4 h, and analysed by flow cytometry.
Culture of lymphoma cells and derivation of cell lines
Normal or lymphomic thymuses were disaggregated by forcing through a nylon mesh and then put in culture in RPMI, 10% FBS. Cultures were maintained by removing medium and excess nonadherent cells every 3 days and replacing with fresh medium. After 7-14 days of culture, cells derived from lymphomas were maintained as pools or cloned by dilution and expanded as cell lines. In contrast to the thymic lymphomas, no proliferation of normal RasGRP1 transgenic thymuses occurred in culture, and no cell lines could be established.
